Disease processes differ from patient to patient
Increase efficacy and safety for the individual patient
Currently, between 20% and 75% of patients respond to a particular therapy, depending on the type of cancer or indication.
It would be very helpful to identify those patients who will or won´t respond to specific treatments, even before starting a therapy.
This way, only patients who are likely to benefit from a particular therapy will be treated. Personalized medicine is about getting the right dose of the right drug to the right patient at the right time, helping the physician to select the optimum treatment for the individual patient´s needs.
Biomarkers for personalized medicine
To detect the differences between responders and non-responders, researchers are trying to identify biomarkers in the different body fluids, tissues and genetic information (DNA). The more precisely a drug discriminates between tumor cells and normal cells, the more powerful its effect on the disease and the lower the risk of side effects.